Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment

Ovarian cancer remains a leading cause of gynecological cancer-related mortality, with epithelial ovarian carcinoma, germ cell tumors, and stromal tumors being the most prevalent types. The disease is classified based on the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and its incidence increases with age. Standard treatment strategies, including taxanes, platinum-based drugs, monoclonal antibodies, and poly (ADP-ribose) polymerase (PARP) inhibitors, as well as emerging gene and immunotherapies, often suffer from significant adverse effects and limited efficacy. To overcome these challenges, advanced drug delivery systems are essential for enhancing therapeutic outcomes while minimizing toxicity. Liposomes have emerged as a promising nanocarrier for targeted drug delivery in ovarian cancer therapy, offering improved drug stability, prolonged circulation time, and enhanced tumor-specific accumulation. Functional modifications, such as ligand conjugation and combination therapies, further optimize their therapeutic potential. This review discusses recent advancements in liposome-based drug delivery for ovarian cancer, highlighting their benefits, challenges, and future directions in improving treatment efficacy.